249
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Evaluation of PAX1/ST6GALNAC5 Methylation as a Triage Test for Cervical Intraepithelial Neoplasia and Cervical Couancer

ORCID Icon, , , , , , , , , , , , , , & show all
Pages 131-145 | Received 07 Nov 2022, Accepted 24 Mar 2023, Published online: 05 Apr 2023

References

  • Sung H , FerlayJ , SiegelRLet al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71(3), 209–249 (2021).
  • Singh D , VignatJ , LorenzoniVet al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob. Health11(2), e197–e206 (2023).
  • Browne S , FeemsterKA. Human papillomavirus: optimizing opportunities for prevention. Curr. Opin. Pediatr.34(2), 132–139 (2022).
  • Khairkhah N , BolhassaniA , NajafipourR. Current and future direction in treatment of HPV-related cervical disease. J. Mol. Med.100(6), 829–845 (2022).
  • Zhou Y , RassyE , CoutteAet al. Current standards in the management of early and locally advanced cervical cancer: update on the benefit of neoadjuvant/adjuvant strategies. Cancers (Basel)14(10), 2449 (2022).
  • Guimaraes YM , GodoyLR , Longatto-FilhoA , ReisRD. Management of early-stage cervical cancer: a literature review. Cancers (Basel)14(3), 575 (2022).
  • Micco M , LupinelliM , MangialardiM , GuiB , ManfrediR. Patterns of recurrent disease in cervical cancer. J. Pers. Med.12(5), 755 (2022).
  • Lemp JM , DeNeve JW , BussmannHet al. Lifetime prevalence of cervical cancer screening in 55 low- and middle-income countries. JAMA324(15), 1532–1542 (2020).
  • Fu K , LeiM , WuLSet al. Triage by PAX1 and ZNF582 methylation in women with cervical intraepithelial neoplasia grade 3: a multicenter case–control study. Open Forum Infect. Dis.9(5), ofac013 (2022).
  • Board PPTE. Childhood Non-Hodgkin Lymphoma Treatment (PDQ) . Cervical Cancer Screening (PDQ®): Health Professional Version. In: Health Professional Version - PDQ Cancer Information Summaries.National Cancer Institute, MD, USA (2002).
  • Kong L , WangL , WangZet al. DNA methylation for cervical cancer screening: a training set in China. Clin. Epigenetics12(1), 91 (2020).
  • Winer RL , KiviatNB , HughesJPet al. Development and duration of human papillomavirus lesions, after initial infection. J. Infect. Dis.191(5), 731–738 (2005).
  • Saslow D , SolomonD , LawsonHWet al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J. Low. Genit. Tract Dis.16(3), 175–204 (2012).
  • Mcgrath CM , KurtisJD , YuGH. Evaluation of mild-to-moderate dysplasia on cervical-endocervical (Pap) smear: a subgroup of patients who bridge LSIL and HSIL. Diagn. Cytopathol.23(4), 245–248 (2000).
  • Walboomers JM , JacobsMV , ManosMMet al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol.189(1), 12–19 (1999).
  • Latsuzbaia A , BroeckDV , Van KeerSet al. Clinical performance of the realtime high risk HPV assay on self-collected vaginal samples within the VALHUDES Framework. Microbiol. Spectr.10(5), e0163122 (2022).
  • Szalmas A , KonyaJ. Epigenetic alterations in cervical carcinogenesis. Semin. Cancer Biol.19(3), 144–152 (2009).
  • Jones A , LechnerM , FourkalaEO , KristeleitR , WidschwendterM. Emerging promise of epigenetics and DNA methylation for the diagnosis and management of women’s cancers. Epigenomics2(1), 9–38 (2010).
  • Bhat S , KabekkoduSP , NoronhaA , SatyamoorthyK. Biological implications and therapeutic significance of DNA methylation regulated genes in cervical cancer. Biochimie121, 298–311 (2016).
  • Ongenaert M , WismanGB , VoldersHHet al. Discovery of DNA methylation markers in cervical cancer using relaxation ranking. BMC Med. Genomics1, 57 (2008).
  • Lai HC , LinYW , HuangTHet al. Identification of novel DNA methylation markers in cervical cancer. Int. J. Cancer123(1), 161–167 (2008).
  • Mersakova S , NachajovaM , SzepeP , KasajovaPS , HalasovaE. DNA methylation and detection of cervical cancer and precancerous lesions using molecular methods. Tumour Biol.37(1), 23–27 (2016).
  • Salta S , Maia-MocoL , Estevao-PereiraHet al. Performance of DNA methylation-based biomarkers in the cervical cancer screening program of northern Portugal: a feasibility study. Int. J. Cancer149(11), 1916–1925 (2021).
  • Widschwendter A , MullerHM , FieglHet al. DNA methylation in serum and tumors of cervical cancer patients. Clin. Cancer Res.10(2), 565–571 (2004).
  • van den Helder R , SteenbergenRDM , Van SplunterAPet al. HPV and DNA methylation testing in urine for cervical intraepithelial neoplasia and cervical cancer detection. Clin. Cancer Res.28(10), 2061–2068 (2022).
  • Zhu H , ZhuH , TianM , WangD , HeJ , XuT. DNA methylation and hydroxymethylation in cervical cancer: diagnosis, prognosis and treatment. Front. Genet.11, 347 (2020).
  • Cardoso MFS , CastellettiCHM , Lima-FilhoJL , MartinsDBG , TeixeiraJAC. Putative biomarkers for cervical cancer: SNVs, methylation and expression profiles. Mutat. Res. Rev. Mutat. Res.773, 161–173 (2017).
  • Zhang L , TanW , YangH , ZhangS , DaiY. Detection of host cell gene/HPV DNA methylation markers: a promising triage approach for cervical cancer. Front. Oncol.12, 831949 (2022).
  • Xu W , XuM , WangLet al. Integrative analysis of DNA methylation and gene expression identified cervical cancer-specific diagnostic biomarkers. Signal Transduct. Target. Ther.4, 55 (2019).
  • Verhoef L , BleekerMCG , PolmanNet al. Performance of DNA methylation analysis of ASCL1, LHX8, ST6GALNAC5, GHSR, ZIC1 and SST for the triage of HPV-positive women: results from a Dutch primary HPV-based screening cohort. Int. J. Cancer150(3), 440–449 (2022).
  • Unanyan A , PivazyanL , DavydovaJet al. Efficacy of photodynamic therapy in women with HSIL, LSIL and early stage squamous cervical cancer: a systematic review and meta-analysis. Photodiagnosis Photodyn. Ther.36, 102530 (2021).
  • Wu MZ , WangS , ZhengMet al. The diagnostic utility of p16 immunostaining in differentiating cancer and HSIL from LSIL and benign in cervical cells. Cell Transplant.28(2), 195–200 (2019).
  • Feng G , BeileiZ , CaizhiC , WenZ. Analysis of CASP12 diagnostic and prognostic values in cervical cancer based on TCGA database. Biosci. Rep.39(12), BSR20192706 (2019).
  • Lando M , FjeldboCS , WiltingSMet al. Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer. Epigenetics10(10), 970–980 (2015).
  • Tian Y , MorrisTJ , WebsterAPet al. ChAMP: updated methylation analysis pipeline for Illumina BeadChips. Bioinformatics33(24), 3982–3984 (2017).
  • Robin X , TurckN , HainardAet al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics12, 77 (2011).
  • Zhang L , ZhaoX , HuS , ChenS , ZhaoS , DongLet al. Triage performance and predictive value of the human gene methylation panel among women positive on self-collected HPV test: results from a prospective cohort study. Int. J. Cancer151(6), 878–887 (2022).
  • Kelly H , BenaventeY , PavonMA , DeSanjose S , MayaudP , LorinczAT. Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): a systematic review and meta-analysis. Br. J. Cancer121(11), 954–965 (2019).
  • Li X , ZhengR , LiXet al. Trends of incidence rate and age at diagnosis for cervical cancer in China, from 2000 to 2014. Chin. J. Cancer Res.29(6), 477–486 (2017).
  • Xia C , DingC , ZhengRet al. Trends in geographical disparities for cervical cancer mortality in China from 1973 to 2013: a subnational spatio-temporal study. Chin. J. Cancer Res.29(6), 487–495 (2017).
  • Yu YQ , HaoJQ , MendezMJG , MohamedSB , FuSL , ZhaoFHet al. The prevalence of cervical HPV infection and genotype distribution in 856,535 Chinese women with normal and abnormal cervical lesions: a systemic review. J. Cytol.39(4), 137–147 (2022).
  • Hoyer H , ScheungraberC , Kuehne-HeidRet al. Cumulative 5-year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high-risk HPV and cytology testing in a primary screening setting. Int. J. Cancer116(1), 136–143 (2005).
  • Guo M , KhannaA , DawlettM , PatelS , GongY , StaerkelG. Efficacy of reflex HPV16/18 genotyping in predicting CIN3/VAIN3 in women with HPV+/Pap- results. J. Am. Soc. Cytopathol.5(1), 31–36 (2016).
  • Guo YL , YouK , GengL , QiaoJ. Clinical performance of APTIMA human papillomavirus (HPV) 16 18/45 mRNA genotyping testing for the detection of cervical intraepithelial neoplasia 3 (CIN3) or cancer in a select group of Chinese women. Pathol. Oncol. Res.22(3), 549–554 (2016).
  • Hammer A , DemarcoM , CamposNet al. A study of the risks of CIN3+ detection after multiple rounds of HPV testing: results of the 15-year cervical cancer screening experience at Kaiser Permanente Northern California. Int. J. Cancer147(6), 1612–1620 (2020).
  • Uijterwaal MH , VerhoefVM , SnijdersPJ , MeijerCJ. Arguments in favor of HPV testing for cervical screening and post-treatment CIN2+ monitoring. Expert Rev. Mol. Diagn.14(3), 245–248 (2014).
  • Bonde J , FlooreA , EjegodDet al. Methylation markers FAM19A4 and miR124-2 as triage strategy for primary human papillomavirus screen positive women: a large European multicenter study. Int. J. Cancer148(2), 396–405 (2021).
  • Vink FJ , MeijerC , CliffordGMet al. FAM19A4/miR124-2 methylation in invasive cervical cancer: a retrospective cross-sectional worldwide study. Int. J. Cancer147(4), 1215–1221 (2020).
  • Banila C , LorinczAT , Scibior-BentkowskaD , CliffordGM , KumbiB , BeyeneDet al. Clinical performance of methylation as a biomarker for cervical carcinoma in situ and cancer diagnosis: a worldwide study. Int. J. Cancer150(2), 290–302 (2022).
  • Farkas SA , Milutin-GasperovN , GrceM , NilssonTK. Genome-wide DNA methylation assay reveals novel candidate biomarker genes in cervical cancer. Epigenetics8(11), 1213–1225 (2013).
  • Su PH , LaiHC , HuangRLet al. Paired box-1 (PAX1) activates multiple phosphatases and inhibits kinase cascades in cervical cancer. Sci. Rep.9(1), 9195 (2019).
  • Luan T , HuaQ , LiuXet al. PAX1 methylation as a potential biomarker to predict the progression of cervical intraepithelial neoplasia: a meta-analysis of related studies. Int. J. Gynecol. Cancer27(7), 1480–1488 (2017).
  • Bos PD , ZhangXH , NadalCet al. Genes that mediate breast cancer metastasis to the brain. Nature459(7249), 1005–1009 (2009).
  • Dick S , VerhoefL , DeStrooper LMet al. Evaluation of six methylation markers derived from genome-wide screens for detection of cervical precancer and cancer. Epigenomics12(18), 1569–1578 (2020).
  • Zhao Z , ZhangX , ZhaoX , CaiJ , WuNY , WangJ. SOX1 and PAX1 are hypermethylated in cervical adenocarcinoma and associated with better prognosis. Biomed. Res. Int.2020, 3981529 (2020).
  • Liu H , MengX , WangJ. Real time quantitative methylation detection of PAX1 gene in cervical cancer screening. Int. J. Gynecol. Cancer30(10), 1488–1492 (2020).
  • Kong LY , DuW , WangL , YangZ , ZhangHS. PAX1 methylation hallmarks promising accuracy for cervical cancer screening in Asians: results from a meta-analysis. Clin Lab61(10), 1471–1479 (2015).
  • Nikolaidis C , NenaE , PanagopoulouMet al. PAX1 methylation as an auxiliary biomarker for cervical cancer screening: a meta-analysis. Cancer Epidemiol.39(5), 682–686 (2015).
  • Kan YY , LiouYL , WangHJet al. PAX1 methylation as a potential biomarker for cervical cancer screening. Int. J. Gynecol. Cancer24(5), 928–934 (2014).
  • Kremer WW , SteenbergenR , HeidemanD , KenterGG , MeijerC. The use of host cell DNA methylation analysis in the detection and management of women with advanced cervical intraepithelial neoplasia: a review. BJOG128(3), 504–514 (2021).
  • Zhang L , YuJ , HuangW , ZhangH , XuJ , CaiH. A sensitive and simplified classifier of cervical lesions based on a methylation-specific PCR assay: a Chinese cohort study. Cancer Manag. Res.12, 2567–2576 (2020).
  • Liang H , LiGL , LiuJet al. The application value of PAX1 and ZNF582 gene methylation in high grade intraepithelial lesion and cervical cancer. Clin. Transl. Oncol.23(2), 283–288 (2021).
  • Chang CL , HoSC , SuYFet al. DNA methylation marker for the triage of hrHPV positive women in cervical cancer screening: real-world evidence in Taiwan. Gynecol. Oncol.161(2), 429–435 (2021).
  • Nourrisson A , LepetitH , MartyM , GarrigueI , BrunJL. Regression of cervical high-grade squamous intraepithelial lesions (HSIL/CIN2) managed expectantly. J. Gynecol. Obstet. Hum. Reprod.51(8), 102442 (2022).
  • Origoni M , CristoforoniP , CarminatiGet al. E6/E7 mRNA testing for human papilloma virus-induced high-grade cervical intraepithelial disease (CIN2/CIN3): a promising perspective. Ecancermedicalscience9, 533 (2015).
  • Papoutsis D . Cervical ablation versus excision for CIN2/3: what is the current evidence?BJOG130(2), 162 (2023).
  • Papoutsis D , PanikkarJ , UnderwoodMet al. Endocervical crypt involvement by CIN2-3 as a predictor of cytology recurrence after excisional cervical treatment. J. Low. Genit. Tract Dis.19(4), 311–318 (2015).
  • Pontes VB , MartinsLFL , SzkloM , MoreiraMÂM , ChavesCBP , de AlmeidaLM. Factors associated with cervical intraepithelial neoplasia (CIN2/CIN3), early stage and advanced stage of cervical cancer diagnosis in the Brazilian Amazonian region. Eur. J. Cancer Prev.29(4), 342–345 (2020).
  • Adcock R , NedjaiB , LorinczATet al. DNA methylation testing with S5 for triage of high-risk HPV positive women. Int. J. Cancer151(7), 993–1004 (2022).
  • van den Helder R , van TrommelNE , van SplunterAP , Lissenberg-WitteBI , BleekerMCG , SteenbergenRDM. Methylation analysis in urine fractions for optimal CIN3 and cervical cancer detection. Papillomavirus Res.9, 100193 (2020).
  • Hampl M , HesselinkAT , MeijerCet al. Evaluation of FAM19A4/miR124-2 methylation performance in the management of CIN3 diagnosed pregnant women. Int. J. Cancer151(9), 1578–1585 (2022).
  • Leeman A , DelPino M , MarimonLet al. Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytology-screened referral population. Int. J. Cancer144(1), 160–168 (2019).
  • Cook DA , KrajdenM , BrentnallAR , GondaraL , ChanT , LawJHet al. Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial. Int. J. Cancer144(10), 2587–2595 (2019).
  • Lazcano-Ponce E , LorinczAT , Cruz-ValdezA , SalmeronJ , UribeP , Velasco-MondragonEet al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet378(9806), 1868–1873 (2011).
  • Lehtinen M , PimenoffVN , NedjaiB , LouvantoK , VerhoefL , HeidemanDAMet al. Assessing the risk of cervical neoplasia in the post-HPV vaccination era. Int. J. Cancer152(6), 1060–1068 (2023).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.